Cargando…
The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aim...
Autores principales: | Huskova, Zlata, Knillova, Jana, Kolar, Zdenek, Vrbkova, Jana, Kral, Milan, Bouchal, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344460/ https://www.ncbi.nlm.nih.gov/pubmed/32630458 http://dx.doi.org/10.3390/biomedicines8060173 |
Ejemplares similares
-
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study
por: Logozzi, Mariantonia, et al.
Publicado: (2019) -
The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer
por: Koliakos, G., et al.
Publicado: (2000) -
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
por: Jia, Gaozhen, et al.
Publicado: (2017) -
Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019) -
Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer
por: Jedinak, Andrej, et al.
Publicado: (2015)